1. Home
  2. ZLAB vs CATY Comparison

ZLAB vs CATY Comparison

Compare ZLAB & CATY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • CATY
  • Stock Information
  • Founded
  • ZLAB 2013
  • CATY 1962
  • Country
  • ZLAB China
  • CATY United States
  • Employees
  • ZLAB N/A
  • CATY N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • CATY Major Banks
  • Sector
  • ZLAB Health Care
  • CATY Finance
  • Exchange
  • ZLAB Nasdaq
  • CATY Nasdaq
  • Market Cap
  • ZLAB 3.4B
  • CATY 3.3B
  • IPO Year
  • ZLAB 2017
  • CATY N/A
  • Fundamental
  • Price
  • ZLAB $33.78
  • CATY $45.86
  • Analyst Decision
  • ZLAB Strong Buy
  • CATY Hold
  • Analyst Count
  • ZLAB 3
  • CATY 5
  • Target Price
  • ZLAB $55.00
  • CATY $50.80
  • AVG Volume (30 Days)
  • ZLAB 752.8K
  • CATY 290.9K
  • Earning Date
  • ZLAB 02-27-2025
  • CATY 01-22-2025
  • Dividend Yield
  • ZLAB N/A
  • CATY 2.97%
  • EPS Growth
  • ZLAB N/A
  • CATY N/A
  • EPS
  • ZLAB N/A
  • CATY 3.95
  • Revenue
  • ZLAB $355,748,000.00
  • CATY $692,219,000.00
  • Revenue This Year
  • ZLAB $49.04
  • CATY N/A
  • Revenue Next Year
  • ZLAB $46.80
  • CATY $7.53
  • P/E Ratio
  • ZLAB N/A
  • CATY $11.61
  • Revenue Growth
  • ZLAB 35.01
  • CATY N/A
  • 52 Week Low
  • ZLAB $13.48
  • CATY $33.88
  • 52 Week High
  • ZLAB $36.60
  • CATY $55.29
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 79.95
  • CATY 40.84
  • Support Level
  • ZLAB $30.61
  • CATY $46.13
  • Resistance Level
  • ZLAB $33.00
  • CATY $47.33
  • Average True Range (ATR)
  • ZLAB 1.32
  • CATY 1.03
  • MACD
  • ZLAB 0.58
  • CATY -0.02
  • Stochastic Oscillator
  • ZLAB 86.34
  • CATY 10.19

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

About CATY Cathay General Bancorp

Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities, and advisory services.

Share on Social Networks: